The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both https://zoegzpe309388.bcbloggers.com/37973356/glp-3-retatrutide-a-comparative-analysis